Jeon Hwa-sung's Startup Morning Coffee #1092: MPIO on Innovation and Growth

Every morning, the YouTube program 'Startup Morning Coffee,' which brings a fresh breath to the startup ecosystem, is garnering keen attention with CEO Jeon Hwa-sung as its host. Broadcast live daily at 8:40 AM on 'Jeon Hwa-sung's CNTV' channel, this program offers an in-depth introduction to the core competencies and boundless market potential of various startups. In particular, interactive communication with viewers through real-time comments has firmly established it as a valuable platform, providing vivid insights beyond mere information delivery to those interested in startups. Recently, the company that gained attention on 'Startup Morning Coffee' is Mpious, a bio-company developing innovative drug delivery system technology. Mpious is attracting the industry's focus with its drug delivery technology that minimizes side effects while maximizing drug efficacy. Specifically, it concentrates on dramatically increasing the solubility of poorly soluble drugs to improve in-vivo absorption and bioavailability, thereby aiming to enhance drug effects while minimizing burdensome side effects for patients. Mpious's core technology is a self-developed transdermal drug delivery platform, which it utilizes to focus on developing 'topical medication' type products. Currently, it is accelerating technology advancement by participating in CNTTech's Kibo Venture Camp support program. The true value of Mpious's technology lies in its drug delivery system that significantly enhances skin permeability while minimizing side effects. This technology is primarily applied to topical acne treatments, dramatically reducing discomforts like skin irritation or dryness caused by existing products, and maximizing the skin penetration of active ingredients to significantly improve therapeutic effects. This greatly contributes to increasing patient compliance by allowing them to receive treatment more comfortably. Mpious's innovative technology holds boundless potential to expand beyond acne treatment to various dermatological disease treatments such as atopic dermatitis in the future. CEO Jeon Hwa-sung strongly assessed Mpious's growth potential, stating, "It will possess unparalleled competitiveness not only in the acne market but also in the broader dermatological treatment market." In a situation where consumer demand for topical agents that reduce side effects while being highly effective is higher than ever, Mpious's innovative drug delivery technology is expected to breathe new life into the market and rapidly grow into a key player in the bio-healthcare sector.